Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion
- PMID: 23254638
- PMCID: PMC4040220
- DOI: 10.3233/JAD-121786
Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion
Abstract
Chronic cerebral hypoperfusion (CCH), featuring in most of the Alzheimer's disease spectrum, plays a detrimental role in brain amyloid-β (Aβ) homeostasis, cerebrovascular morbidity, and cognitive decline; therefore, early management of cerebrovascular pathology is considered to be important for intervention in the impending cognitive decline. S-nitrosoglutathione (GSNO) is an endogenous nitric oxide carrier modulating endothelial function, inflammation, and neurotransmission. Therefore, the effect of GSNO treatment on CCH-associated neurocognitive pathologies was determined in vivo by using rats with permanent bilateral common carotid artery occlusion (BCCAO), a rat model of chronic cerebral hypoperfusion. We observed that rats subjected to permanent BCCAO showed a significant decrease in learning/memory performance and increases in brain levels of Aβ and vascular inflammatory markers. GSNO treatment (50 μg/kg/day for 2 months) significantly improved learning and memory performance of BCCAO rats and reduced the Aβ levels and ICAM-1/VCAM-1 expression in the brain. Further, in in vitro cell culture studies, GSNO treatment also decreased the cytokine-induced proinflammatory responses, such as activations of NFκB and STAT3 and expression of ICAM-1 and VCAM-1 in endothelial cells. In addition, GSNO treatment increased the endothelial and microglial Aβ uptake. Additionally, GSNO treatment inhibited the β-secretase activity in primary rat neuron cell culture, thus reducing secretion of Aβ, suggesting GSNO mediated mechanisms in anti-inflammatory and anti-amyloidogenic activities. Taken together, these data document that systemic GSNO treatment is beneficial for improvement of cognitive decline under the conditions of chronic cerebral hypoperfusion and suggests a potential therapeutic use of GSNO for cerebral hypoperfusion associated mild cognitive impairment in Alzheimer's disease.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4040220/bin/nihms569802f1.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4040220/bin/nihms569802f2.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4040220/bin/nihms569802f3.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4040220/bin/nihms569802f4.gif)
Similar articles
-
S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion.Brain Res. 2015 Oct 22;1624:359-369. doi: 10.1016/j.brainres.2015.07.057. Epub 2015 Aug 10. Brain Res. 2015. PMID: 26271717 Free PMC article.
-
Icariin, a major constituent of flavonoids from Epimedium brevicornum, protects against cognitive deficits induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats.Pharmacol Biochem Behav. 2015 Nov;138:40-8. doi: 10.1016/j.pbb.2015.09.001. Epub 2015 Sep 11. Pharmacol Biochem Behav. 2015. PMID: 26364923
-
S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats.J Neuroinflammation. 2011 Jul 6;8:78. doi: 10.1186/1742-2094-8-78. J Neuroinflammation. 2011. PMID: 21733162 Free PMC article.
-
Remote Ischemic Conditioning: A Potential Treatment for Chronic Cerebral Hypoperfusion.Eur Neurol. 2022;85(4):253-259. doi: 10.1159/000521803. Epub 2022 Feb 1. Eur Neurol. 2022. PMID: 35104816 Review.
-
Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress.Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):953-9. doi: 10.1007/s00210-012-0790-7. Epub 2012 Aug 8. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22872171 Review.
Cited by
-
The effects of nitric oxide in Alzheimer's disease.Med Gas Res. 2024 Dec 1;14(4):186-191. doi: 10.4103/2045-9912.385939. Epub 2023 Sep 17. Med Gas Res. 2024. PMID: 39073326 Free PMC article. Review.
-
A circRNA ceRNA network involved in cognitive dysfunction after chronic cerebral hypoperfusion.Aging (Albany NY). 2024 Jan 16;16(2):1161-1181. doi: 10.18632/aging.205387. Epub 2024 Jan 16. Aging (Albany NY). 2024. PMID: 38231472 Free PMC article.
-
Kapβ2 Inhibits Perioperative Neurocognitive Disorders in Rats with Mild Cognitive Impairment by Reversing the Nuclear-Cytoplasmic Mislocalization of hnRNPA2/B1.Mol Neurobiol. 2024 Jul;61(7):4488-4507. doi: 10.1007/s12035-023-03789-8. Epub 2023 Dec 16. Mol Neurobiol. 2024. PMID: 38102516
-
Effect of β-amyloid on blood-brain barrier properties and function.Biophys Rev. 2023 Apr 5;15(2):183-197. doi: 10.1007/s12551-023-01052-x. eCollection 2023 Apr. Biophys Rev. 2023. PMID: 37124923 Free PMC article. Review.
-
Endothelial Dysfunction in Neurodegenerative Diseases.Int J Mol Sci. 2023 Feb 2;24(3):2909. doi: 10.3390/ijms24032909. Int J Mol Sci. 2023. PMID: 36769234 Free PMC article. Review.
References
-
- de la Torre JC. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int Rev Neurobiol. 2009;84:35–48. - PubMed
-
- de la Torre JC. Alzheimer's disease is a vasocognopathy: A new term to describe its nature. Neurol Res. 2004;26:517–524. - PubMed
-
- de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke. 2002;33:1152–1162. - PubMed
-
- Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation. 2004;109:II27–II33. - PubMed
-
- Braam B, Verhaar MC. Understanding eNOS for pharmacological modulation of endothelial function: A translational view. Curr Pharm Des. 2007;13:1727–1740. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous